137 related articles for article (PubMed ID: 32524735)
1. Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects.
Kuriyama N; Matsumoto K; Morita K; Shimomura Y; Hara Y; Hasegawa D; Nakamura T; Yamashita C; Kato Y; Komura H; Nishida O
Ther Apher Dial; 2020 Oct; 24(5):499-502. PubMed ID: 32524735
[TBL] [Abstract][Full Text] [Related]
2. Effects of nafamostat mesilate on 5-hydroxytryptamine release from isolated ileal tissues induced by anti-cancer drugs in rats.
Kikuchi K; Hamaue N; Machida T; Iizuka K; Minami M; Hirafuji M
Biomed Res; 2020; 41(5):253-257. PubMed ID: 33071261
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
[TBL] [Abstract][Full Text] [Related]
4. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
Lee YK; Lee HW; Choi KH; Kim BS
PLoS One; 2014; 9(10):e108737. PubMed ID: 25302581
[TBL] [Abstract][Full Text] [Related]
5. Adsorption of Nafamostat Mesilate on AN69ST Membranes: A Single-Center Retrospective and In Vitro Study.
Nakamura Y; Hara S; Hatomoto H; Yamasaki S; Nakano T; Miyazaki M; Matsumoto N; Irie Y; Ishikura H
Ther Apher Dial; 2017 Dec; 21(6):620-627. PubMed ID: 28960755
[TBL] [Abstract][Full Text] [Related]
6. Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.
Yates AG; Weglinski CM; Ying Y; Dunstan IK; Strekalova T; Anthony DC
J Neuroinflammation; 2022 Jan; 19(1):8. PubMed ID: 34991643
[TBL] [Abstract][Full Text] [Related]
7. Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.
Lee JK; Ryu JK; Park JK; Lee SH; Yoon WJ; Kim YT; Jung HC; Yoon YB
Pancreas; 2008 Apr; 36(3):255-60. PubMed ID: 18362838
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
[TBL] [Abstract][Full Text] [Related]
9. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.
Sendo T; Itoh Y; Goromaru T; Sumimura T; Saito M; Aki K; Yano T; Oishi R
Br J Pharmacol; 2003 Mar; 138(5):959-67. PubMed ID: 12642398
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
Doucet JJ; Hoyt DB; Coimbra R; Schmid-Schönbein GW; Junger WG; Paul L W; Loomis WH; Hugli TE
J Trauma; 2004 Mar; 56(3):501-10; discussion 510-1. PubMed ID: 15128119
[TBL] [Abstract][Full Text] [Related]
11. The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice.
Yamaya M; Shimotai Y; Ohkawara A; Bazarragchaa E; Okamatsu M; Sakoda Y; Kida H; Nishimura H
J Med Virol; 2021 Jun; 93(6):3484-3495. PubMed ID: 33247612
[TBL] [Abstract][Full Text] [Related]
12. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
Miyatake Y; Makino S; Kubota K; Egi M; Mizobuchi S
Kobe J Med Sci; 2017 Aug; 63(1):E30-E36. PubMed ID: 29434171
[TBL] [Abstract][Full Text] [Related]
13. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
Fujiwara Y; Furukawa K; Haruki K; Shimada Y; Iida T; Shiba H; Uwagawa T; Ohashi T; Yanaga K
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):731-9. PubMed ID: 21484229
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
15. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
Choi JY; Kang YJ; Jang HM; Jung HY; Cho JH; Park SH; Kim YL; Kim CD
Medicine (Baltimore); 2015 Dec; 94(52):e2392. PubMed ID: 26717390
[TBL] [Abstract][Full Text] [Related]
16. Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma.
Ishizaki M; Tanaka H; Kajiwara D; Toyohara T; Wakahara K; Inagaki N; Nagai H
J Pharmacol Sci; 2008 Nov; 108(3):355-63. PubMed ID: 19008643
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium.
Kim YH; Go YK; Lee JU; Chung WS; Shin YS; Han KC; Shin JE; Lee SH
J Anesth; 2010 Aug; 24(4):549-52. PubMed ID: 20499255
[TBL] [Abstract][Full Text] [Related]
18. Nafamostat mesilate, a kallikrein inhibitor, prevents pain on injection with propofol.
Iwama H; Nakane M; Ohmori S; Kaneko T; Kato M; Watanabe K; Okuaki A
Br J Anaesth; 1998 Dec; 81(6):963-4. PubMed ID: 10211027
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
Shirai Y; Shiba H; Iwase R; Haruki K; Fujiwara Y; Furukawa K; Uwagawa T; Ohashi T; Yanaga K
Cancer Lett; 2016 Jan; 370(2):177-84. PubMed ID: 26546875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
